...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of International Medical Research >Ezetimibe Reduces Urinary Albumin Excretion in Hypercholesterolaemic Type 2 Diabetes Patients with Microalbuminuria
【24h】

Ezetimibe Reduces Urinary Albumin Excretion in Hypercholesterolaemic Type 2 Diabetes Patients with Microalbuminuria

机译：依泽替米贝减少微白蛋白尿症的高胆固醇血症2型糖尿病患者尿白蛋白排泄

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: This study investigated the effects of ezetimibe, an inhibitor of intestinal cholesterol absorption, on early phase diabetic nephropathy. METHODS: A total of 32 hypercholesterolaemic type 2 diabetes patients with microalbuminuria, defined as a urinary albumin excretion (UAE) ≥ 30 but < 300 mg/g creatinine, were enrolled. Various clinical and laboratory parameters were determined at baseline and after 6 months of treatment with 10 mg/day ezetimibe. RESULTS: Ezetimibe treatment significantly decreased glycated haemoglobin (HbA1c), low-density lipoprotein-cholesterol (LDL-C), triglycerides and UAE, and significantly increased high-density lipoprotein-cholesterol and albumin. It also decreased the serum level of monocyte chemoattractant protein-1 (MCP-1), but this difference was not statistically significant. Univariate analyses showed a correlation between UAE and body mass index, systolic and diastolic blood pressures, HbA1c, LDL-C, estimated glomerular filtration rate (inverse), creatinine and MCP-1. Since these parameters may be closely correlated with each other, multiple stepwise regression analysis was performed and demonstrated that HbA1c and MCP-1 were independent determinants of UAE. CONCLUSIONS: Ezetimibe may be a promising therapeutic strategy for improving albumin excretion, partly through its anti-inflammatory properties, and for reducing LDL-C in hypercholesterolaemic type 2 diabetes patients with microalbuminuria.
机译：目的：本研究调查了肠胆固醇吸收抑制剂依泽替米贝对早期糖尿病肾病的影响。方法：共纳入32例微量白蛋白尿的高胆固醇血症2型糖尿病患者，定义为尿白蛋白排泄（UAE）≥30但<300 mg / g肌酐。在基线和使用10 mg /天依泽替米贝治疗6个月后确定了各种临床和实验室参数。结果：依泽替米贝治疗显着降低了糖化血红蛋白（HbA1c），低密度脂蛋白胆固醇（LDL-C），甘油三酸酯和阿联酋，并显着增加了高密度脂蛋白胆固醇和白蛋白。它还降低了单核细胞趋化蛋白-1（MCP-1）的血清水平，但这种差异在统计学上没有统计学意义。单变量分析显示，阿联酋与体重指数，收缩压和舒张压，HbA1c，LDL-C，估计的肾小球滤过率（倒数），肌酐和MCP-1之间存在相关性。由于这些参数可能彼此紧密相关，因此进行了多步逐步回归分析，并证明HbA1c和MCP-1是阿联酋的独立决定因素。结论：依泽替米贝可能是改善白蛋白排泄的一种有前途的治疗策略，部分是通过其抗炎特性，以及减少高胆固醇血症2型糖尿病伴微量白蛋白尿的LDL-C。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号